Critics of Biogen are not impressed by the company’s plan to cut the annual price of its Alzheimer’s drug Aduhelm from $56,000 to $28,000. The price cut comes after months of pushback against the drug’s price. Private insurers and Medicaid directors say there is little evidence the drug works and there is ample evidence of its serious side effects. The company announced this month that it expects to complete the post-market trial of Aduhelm in four years instead of nine...